Calamos Advisors’s Evolent Health EVH Stock Holding History

Calamos Advisors’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-171,704	Closed	-$6.17M	–	1263
2022 Q3	$6.17M	Buy	+171,704	New	+$6.05M	0.03%	618

Other funds holding EVH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Calamos Advisors's EVH Position: Q4 2022 in Review

Calamos Advisors sold out of Evolent Health (EVH) in Q4 2022, closing a stake of 171,704 shares — an estimated $6.17M sold.

Calamos Advisors first reported a position in EVH in Q3 2022 and held it in 1 quarter. The position peaked at $6.17M in Q3 2022. 232 funds tracked by Wall St. Rank hold EVH as of Q4 2022.

Calamos Advisors reported no remaining Evolent Health position as of Q4 2022 after selling out during the quarter.
Calamos Advisors sold 171,704 Evolent Health shares in Q4 2022, an estimated $6.17M.
Calamos Advisors first reported a position in Evolent Health in Q3 2022 and held it in 1 quarter.
Calamos Advisors's Evolent Health position peaked at $6.17M in Q3 2022.
232 funds tracked by Wall St. Rank held Evolent Health as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.